

## Sepsis grave y shock séptico

### Referencias bibliográficas

Se autoriza el uso, copia y distribución de este documento. No está permitida su modificación.

#### **Cómo citar este documento:**

Palencia E. Sepsis grave y shock séptico: referencias bibliográficas. REMI 2006; 6 (10): A55.  
URL: <http://remi.uninet.edu/2006/10/REMIA055.htm>

#### **Como utilizar el documento:**

El documento se encuentra en formato PDF de Adobe. Al abrirlo aparece en la parte izquierda de la pantalla el **índice de contenidos**, en la pestaña de “Marcadores”; pulsando sobre cualquiera de ellos, irá a la sección correspondiente. Cada sección contiene una selección de las referencias bibliográficas consideradas de mayor interés, en formato Vancouver, acompañadas por **enlaces** activos al resumen del artículo y los artículos relacionados en Medline, y, cuando está disponible gratuitamente, también al texto completo del mismo. En cada sección las referencias están numeradas y en orden alfabético del primer autor.

Puede **buscar dentro del documento**, yendo al elemento del menú [*Edición/Buscar*], o mediante el método abreviado por teclado [*Control+F*]. Así, puede localizar fácilmente los artículos escritos por un autor determinado, los publicados en determinada revista, los publicados en determinado año o los que contengan en su título alguna palabra concreta.

Puede **copiar las referencias** que desee para pegarlas en su propio documento, mediante los métodos estándar de Windows™ [*Edición/Copiar*] o [*Control+C*] para copiar, [*Edición/Pegar*] o [*Control+V*] para pegar.

Esta es la primera versión de este documento, que se actualizará periódicamente. Las próximas versiones presentarán mejoras, corregirán errores y añadirán nuevas referencias. Se agradecerá cualquier opinión, rectificación o sugerencia de los lectores. Las nuevas versiones de este documento se publicarán en REMI: <http://remi.uninet.edu/sepsis/referencias.htm>

Eduardo Palencia Herrejón  
Servicio de Medicina Intensiva  
Hospital Gregorio Marañón, Madrid.  
Correo electrónico:  
[palenciah@gmail.com](mailto:palenciah@gmail.com)  
[remi@uninet.edu](mailto:remi@uninet.edu)

### ***Referencias generales***

1. de Lucas N. Manejo de la sepsis grave en el neonato. [REMI 2005; 5 \(6\): C31.](#)
2. Díaz-Alersi R. Tratamiento hemodinámico del shock séptico. [REMI 2004; 4 \(11\): C18.](#)
3. López-Herce J. Manejo de la sepsis grave en el niño. [REMI 2004; 4 \(8\): C30.](#)
4. Palencia E. Conferencias de consenso e iniciativas para combatir a la sepsis. [REMI 2004; 4 \(10\): C2.](#)
5. Palencia E. Epidemiología de la sepsis. [REMI 2004; 4 \(7\): C1.](#)
6. Palencia E. La sepsis: definiciones y estadios. [REMI 2004; 4 \(6\): C1.](#)
7. Palencia E. Tratamiento del enfermo con sepsis grave. [REMI 2005; 5 \(3\): C3.](#)
8. Sierra R. Sepsis grave y shock séptico: aspectos etiopatogénicos, fisiopatológicos, clínicos y terapéuticos. Tercer Congreso Internacional de Medicina Crítica en Internet, 2001. [[Texto completo](#)]

### ***Pautas de actuación clínica***

1. Carcillo JA, Fields AI, Task Force Comittee Members. ACCM clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med 2002; 30: 1365-1378. [[Resumen](#)] [[Artículos relacionados](#)] [[PDF 1,29 Mb](#)]
2. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM. Surviving Sepsis Campaign Guidelines for the management of severe sepsis and septic shock. Intensive Care Med 2004; 30: 536-555. [[Resumen](#)] [[Artículos relacionados](#)] [[PDF 273 Kb, 20 pág.](#)]. Crit Care Med 2004; 32: 858-873. [[PDF 16 pág](#)]
3. Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, Dasta JF, Heard SO, Martin C, Napolitano LM, Susla GM, Totaro R, Vincent JL, Zanotti-Cavazzoni S. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004; 32: 1928-1948. [[Resumen](#)] [[Artículos relacionados](#)] [[PDF 799 Kb, 21 pág](#)]
4. Institute for Healthcare Improvement: Sepsis. [[Enlace](#)]
5. Nguyen HB, Rivers EP, Abrahamian FM, Moran GJ, Abraham E, Trzeciak S, Huang DT, Osborn T, Stevens D, Talan DA, Emergency Department Sepsis Education Program and Strategies to Improve Survival (ED-SEPSIS) Working Group. Severe Sepsis and Septic Shock: Review of the Literature and Emergency Department Management Guidelines. [[Resumen](#)] [[Artículos relacionados](#)]
6. Palencia E. Pautas de actuación clínica sobre sepsis grave y shock séptico. [[REMI 2004; 4 \(3\) A15](#)]
7. Pronovost PJ, Nolan T, Zeger S, Miller M, Rubin H. How can clinicians measure safety and quality in acute care?. Lancet 2004; 363: 1061-1067. [[Resumen](#)] [[Artículos relacionados](#)]
8. Sprung ChL, Bernard GR, Dellinger P; International Sepsis Forum. Guidelines for the management of severe sepsis and septic shock. Intensive Care Med 2001; 27 Suppl 1: S1-S134. [[Búsqueda Medline](#)]
9. Surviving Sepsis Campaign. Barcelona Declaration. [[Texto completo](#)]
10. Vincent JL. Is the Current Management of Severe Sepsis and Septic Shock Really Evidence Based?. PLOS Medicine 2006; 3. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]

## ***Puesta en práctica***

1. De Miguel-Yanes JM, Andueza-Lillo JA, González-Ramallo VJ, Pastor L, Muñoz J. Failure to implement evidence-based clinical guidelines for sepsis at the ED. *Am J Emerg Med* 2006; 24: 553-559. [[Resumen](#)] [[Artículos relacionados](#)]
2. Gao F, Melody T, Daniels DF, Giles S, Fox S. The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study. *Crit Care* 2005; 9: 764-770. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
3. Institute for Healthcare Improvement. Sepsis: How to improve. [[Enlace](#)]
4. Kortgen A, Niederprum P, Bauer M. Implementation of an evidence-based “standard operating procedure” and outcome in septic shock. *Crit Care Med* 2006; 34: 943-949. [[Resumen](#)] [[Artículos relacionados](#)]
5. Micek ST, Roubinian N, Heuring T, Bode M, Williams J, Harrison C, Murphy T, Prentice D, Ruoff BE, Kollef MH. Before-after study of a standardized hospital order set for the management of septic shock. *Crit Care Med* 2006; 34 (en prensa) [[Resumen](#)] [[Artículos relacionados](#)]
6. Nguyen HB, Corbett SW, Menes K, Cho T, Daugharthy J, Klein W, Withlake WA. Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department. *Acad Emerg Med* 2006; 13: 109-113. [[Resumen](#)] [[Artículos relacionados](#)]
7. Palencia E. Manos a la obra: disminuir la mortalidad de la sepsis grave. [[REMI 2006; 6 \(3\): A41](#)]
8. Pronovost PJ, Nolan T, Zeger S, Miller M, Rubin H. How can clinicians measure safety and quality in acute care?. *Lancet* 2004; 363: 1061-1067. [[Resumen](#)] [[Artículos relacionados](#)]
9. Rivers EP. Early Goal-Directed Therapy in severe sepsis and septic shock. Converting science to reality. *Chest* 2006; 129: 217-218. [[PubMed](#)] [[Artículos relacionados](#)]
10. Shapiro NI, Howell MD, Talmor D, Lahey D, Ngo L, Buras J, Wolfe RE, Weiss JW, Lisbon A. Implementation and outcomes of the multiple urgent sepsis therapies (MUST) protocol. *Crit Care Med* 2006; 34: 1025-1032. [[Resumen](#)] [[Artículos relacionados](#)]
11. Society of Critical Care Medicine. Sepsis Information Home [[Enlace](#)]
12. Surviving Sepsis Campaign [[Enlace](#)]
13. Trzeciak S, Dellinger RP, Abate NL, Cowan RM, Stauss M, Kilgannon JH, Zanotti S, Parrillo JE. Translating research to clinical practice. A 1-year experience with implementing early goal-directed therapy for septic shock in the emergency department. *Chest* 2006; 129: 225-232. [[Resumen](#)] [[Artículos relacionados](#)]

## ***La sepsis: definiciones, estadios, epidemiología***

1. Alberti C, Brun-Buisson C, Goodman SV, Guidici D, Granton J, Moreno R, Smithies M, Thomas O, Artigas A, Le Gall JR; European Sepsis Group. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. *Am J Respir Crit Care Med* 2003; 168: 77-84. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
2. Angus DC, Burgner D, Wunderink R, Mira JP, Gerlach H, Wiedermann CJ, Vincent JL. The PIRO concept: P is for predisposition. *Crit Care* 2003; 7: 248-251. [[Artículos relacionados](#)] [[Texto completo](#)]
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. *Crit Care Med* 2001; 29: 1303-1310. [[Resumen](#)] [[Artículos relacionados](#)]
4. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B, for the CUB-Réa Network. Current epidemiology of septic shock. *Am J Respir Crit Care Med* 2003; 168: 165-172. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
5. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RMH, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* 1992; 101: 1644-1655. [[Resumen](#)] [[Artículos relacionados](#)]
6. Brun-Buisson C, Doyon F, Carlet J, and the French Bacteremia-sepsis study group. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. *Am J Respir Crit Care Med* 1996; 154: 617-624. [[Resumen](#)] [[Artículos relacionados](#)]
7. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Regnier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. *JAMA* 1995; 274: 968-974. [[Resumen](#)] [[Artículos relacionados](#)]
8. Brun-Buisson C, Meshaka P, Pinton P, Vallet B; EPISEPSIS Study Group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. *Intensive Care Med* 2004; 30: 580-588. [[Resumen](#)] [[Artículos relacionados](#)]
9. Brun-Buisson C. The epidemiology of the systemic inflammatory response. *Intensive Care Med* 2000; 26: S64-S74. [[Resumen](#)] [[Artículos relacionados](#)]
10. Centers for Disease Control. Current trends increase in hospital discharge survey rates for septicaemia: United States, 1979-1987. *MMWR* 1990; 39: 31-34. [[Texto completo](#)]
11. Cohen J, Cristofaro P, Carlet J, Opal S. New method of classifying infections in critically ill patients. *Crit Care Med* 2004; 32: 1510-1526. [[Resumen](#)] [[Artículos relacionados](#)]
12. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. *JAMA* 2001; 286: 1754-1758. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]

**Sepsis grave y shock séptico: referencias bibliográficas. Versión 1, octubre 2006.**

**Autor: Eduardo Palencia Herrejón. [REMI 2006; 6 \(10\): A55.](#)**

13. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J and ANZICS Clinical Trials Group Sepsis Investigators. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. *Intensive Care Med* 2004; 30: 589-596. [[Resumen](#)] [[Artículos relacionados](#)]
14. Flaaten H. Epidemiology of sepsis in Norway in 1999. *Crit Care* 2004; 8: 180-184. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
15. Gerlach H, Dhainaut JF, Harbarth S, Reinhart K, Marshall JC, Levy M. The PIRO concept: R is for response. *Crit Care* 2003; 7: 256-259. [[Artículos relacionados](#)] [[Texto completo](#)]
16. Iñigo J, Sendra JM, Díaz R, Bouza C, Sarría-Santamera A. Epidemiología y costes de la sepsis grave en Madrid. Estudio de altas hospitalarias. *Med Intensiva* 2006; 30: 197-203. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)] [[PDF](#) 164 Kb]
17. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; International Sepsis Definitions Conference. 2001 SCCM/ ESICM/ ACCP/ ATS/ SIS International Sepsis Definitions Conference. *Intensive Care Med* 2003; 29: 530-538. [[Resumen](#)] [[Artículos relacionados](#)] El texto completo está disponible gratis en la web de la SCCM: *Crit Care Med* 2003; 31: 1250-1256. [[PDF](#) 282 Kb, 7 pág]
18. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. *N Engl J Med* 2003; 348: 1546-1554. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
19. Matot I, Sprung C. Definition of sepsis. *Intensive Care Med* 2001; 27: S3-S9. [[Resumen](#)] [[Artículos relacionados](#)]
20. Moreno R, Vincent JL, Matos R, Mendonca A, Cantraine F, Thijs L, Takala J, Sprung C, Antonelli M, Bruining H, Willatts S. The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM. *Intensive Care Med* 1999; 25: 686-696. [[Resumen](#)] [[Artículos relacionados](#)]
21. Moss M, Martin GS. A global perspective on the epidemiology of sepsis. *Intensive Care Med* 2004; 30: 527-529. [[Resumen](#)] [[Artículos relacionados](#)]
22. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hours in intensive care units in England, Wales and Northern Ireland. *Crit Care Med* 2003; 31: 2332-2338. [[Resumen](#)] [[Artículos relacionados](#)]
23. Palencia E, Sánchez B. Infecciones del sistema nervioso central: epidemiología de la meningitis aguda. En Serrano R, Barberán J. "Protocolos de enfermedades infecciosas", Sociedad Española de Medicina Interna, 2004. [[Texto completo](#)]
24. Palencia E. Definiciones y estadios de la sepsis. [[REMI 2004; 4 \(6\): C1](#)]
25. Palencia E. Epidemiología de la sepsis. [[REMI 2004; 4 \(7\): C1b](#)]
26. Quartin AA, Schein RM, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. *JAMA* 1997; 277: 1058-1063. [[Resumen](#)] [[Artículos relacionados](#)]
27. Rangel-Frausto MS, Pittet D, Hwang T, Woolson RF, Wenzel R. The dynamics of disease progression in sepsis: Markov modeling describing the natural history and the likely impact of effective antisepsis agents. *Clin Infect Dis* 1998; 27: 185-190. [[Resumen](#)] [[Artículos](#)]

[relacionados\]](#)

28. Rangel-Frausto S, Pittet D, Costignan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. *JAMA* 1995; 273: 117-123. [[Resumen](#)] [[Artículos relacionados](#)]
29. Silva E, de Almeida M, Beltrami AC, et al. Brazilian sepsis epidemiologic study (BASES study). *Crit Care* 2004, 8: R251-R260. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
30. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D; Sepsis Occurrence in Acutely Ill Patients Investigators. Sepsis in European intensive care units: results of the SOAP study. *Crit Care Med* 2006; 34: 344-353. [[Resumen](#)] [[Artículos relacionados](#)]
31. Sprung CL, Sakr Y, Vincent JL, Le Gall JR, Reinhart K, Ranieri VM, Gerlach H, Fielden J, Groba CB, Payen D. An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence in Acutely Ill Patients (SOAP study). *Intensive Care Med* 2006; 32: 421-427. [[Resumen](#)] [[Artículos relacionados](#)]
32. Teres D, Rapoport J, Lemeshow S, Kim S, Akhras K. Effects of severity of illness on resource use by survivors and nonsurvivors of severe sepsis at intensive care admission. *Crit Care Med* 2002; 30: 2413-2419. [[Resumen](#)] [[Artículos relacionados](#)]
33. van Gestel PA, Bakker J, Veraart CPWM, van Hout BA. Prevalence and incidence of severe sepsis in Dutch intensive care units. *Crit Care* 2004; 8: 153-162. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
34. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. *Crit Care Med* 1998; 26: 1793-1800. [[Resumen](#)] [[Artículos relacionados](#)]
35. Vincent JL, Opal S, Torres A, Bonten M, Cohen J, Wunderink R. The PIRO concept: I is for infection. *Crit Care* 2003; 7: 252-255. [[Artículos relacionados](#)] [[Texto completo](#)]
36. Vincent JL, Wendon J, Groeneveld J, Marshall JC, Streat S, Carlet J. The PIRO concept: O is for organ dysfunction. *Crit Care* 2003; 7: 260-264. [[Artículos relacionados](#)] [[Texto completo](#)]
37. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. *Am J Respir Crit Care Med* 2003; 167: 695-701. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
38. Weicker D, Akhras KS, Edelsberg J, Angus DC, Ester G. Long-term mortality and medical care charges in patients with severe sepsis. *Crit Care Med* 2003; 31: 2316-2323. [[Resumen](#)] [[Artículos relacionados](#)]
39. Wenzel RP, Edmond MB. Severe sepsis: National estimates (editorials). *Crit Care Med* 2001; 29: 1472-1473. [[Artículos relacionados](#)]

40. Williams MD, Braun LA, Cooper LM, Johnston J, Weiss RV, Qualy RL, Linde-Zwirble W. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality, and associated costs of care. Crit Care 2004; 8: 291-298. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]



### ***Estatinas y sepsis***

1. Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. *Lancet* 2006; 367: 413-418. [[Resumen](#)] [[Artículos relacionados](#)]
2. Almog Y, Shefer A, Novack V, Maimon N, Barski L, Eizinger M, Friger M, Zeller L, Danon A. Prior statin therapy is associated with a decreased rate of severe sepsis. *Circulation* 2004; 110: 880-885. [[Resumen](#)] [[Artículos relacionados](#)]
3. Liappis AP, Kan VL, Rochester CG, Simon GL. The effect of statins on mortality in patients with bacteremia. *Clin Infect Dis* 2001; 33: 1352-1357. [[Resumen](#)] [[Artículos relacionados](#)]

## **Resucitación inicial y manejo hemodinámico**

1. Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE. Vasopressor and inotropic support in septic shock: An evidence-based review. *Crit Care Med* 2004; 32 (Suppl.): S455-S465. [[Resumen](#)] [[Artículos relacionados](#)]
2. Bindels AJ, van der Hoeven JG, Graafland AD, de Koning J, Meinders AE. Relationships between volume and pressure measurements and stroke volume in critically ill patients. *Crit Care* 2000; 4: 193-199. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
3. Carcillo JA, Fields AI, Task Force Committee Members. ACCM clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. *Crit Care Med* 2002; 30: 1365-1378. [[Resumen](#)] [[Artículos relacionados](#)] [[PDF](#) 1,29 Mb]
4. Day NP, Phu NH, Bethell DP, Mai NT, Chau TT, Hien TT, White NJ. The effects of dopamine and adrenaline infusions on acid-base balance and systemic haemodynamics in severe infection. *Lancet* 1996; 348: 219-223. [[Resumen](#)] [[Artículos relacionados](#)]
5. Debaveye YA, Van den Berghe GH. Is there still a place for dopamine in the modern intensive care unit? *Anesth Analg* 2004; 98: 461-468. [[Resumen](#)] [[Artículos relacionados](#)]
6. Desjars P, Pinaud M, Bugnon D, Tasseau F. Norepinephrine therapy has no deleterious renal effects in human septic shock. *Crit Care Med* 1989; 17: 426-429. [[Resumen](#)] [[Artículos relacionados](#)]
7. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med* 2004; 350: 2247-2256. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
8. Gattinoni L, Brazzi L, Pelosi P, Latini R, Tognoni G, Pesenti A, Fumagalli R. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO<sub>2</sub> Collaborative Group. *N Engl J Med* 1995; 333: 1025-1032. [[Resumen](#)] [[Artículos relacionados](#)]
9. Hayes MA, Timmins AC, Yau EH, Palazzo M, Hinds CJ, Watson D. Elevation of systemic oxygen delivery in the treatment of critically ill patients. *N Engl J Med* 1994; 330: 1717-1722. [[Resumen](#)] [[Artículos relacionados](#)]
10. Heyland DK, Cook DJ, King D, Kernerman P, Brun-Buisson C. Maximizing oxygen delivery in critically ill patients: a methodologic appraisal of the evidence. *Crit Care Med* 1996; 24: 517-524. [[Resumen](#)] [[Artículos relacionados](#)]
11. Hollenberg SM, Ahrens TS, Annane D, Astiz ME, Chalfin DB, Dasta JF, Heard SO, Martin C, Napolitano LM, Susla GM, Totaro R, Vincent JL, Zanotti-Cavazzoni S. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. *Crit Care Med* 2004; 32: 1928-1948. [[Resumen](#)] [[Artículos relacionados](#)] [[PDF](#) 799 Kb, 21 pág]
12. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. *Chest* 2001; 120: 989-1002. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
13. Holmes CL, Walley KR. Bad medicine: low-dose dopamine in the ICU. *Chest* 2003; 123: 1266-1275. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
14. Jardin F, Sportiche M, Bazin M, Bourokba A, Margairaz A. Dobutamine: a hemodynamic evaluation in human septic shock. *Crit Care Med* 1981; 9: 329-332. [[Resumen](#)] [[Artículos](#)]

[relacionados](#)]

- 15.Landry DW, Oliver JA. The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345: 588-595. [[Resumen](#)] [[Artículos relacionados](#)]
- 16.Levy B, Bollaert PE, Charpentier C, Nace L, Audibert G, Bauer P, Nabet P, Larcan A. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 1997; 23: 282-287. [[Resumen](#)] [[Artículos relacionados](#)]
- 17.Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994; 272: 1354-1357. [[Resumen](#)] [[Artículos relacionados](#)]
- 18.Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993; 269: 3024-3029. [[Resumen](#)] [[Artículos relacionados](#)]
- 19.Marik PE, Varon J. Goal-directed therapy for severe sepsis. N Engl J Med 2002; 346: 1025-1026. [[Resumen](#)] [[Artículos relacionados](#)]
- 20.Marik PE, Varon J. The hemodynamic derangements in sepsis: implications for treatment strategies. Chest 1998; 114: 854-860. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
- 21.Marik PE. Sublingual capnography: a clinical validation study. Chest 2001; 120: 923-927. [[Resumen](#)] [[Texto completo](#)]
- 22.Martin C, Eon B, Saux P, Aknin P, Gouin F. Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med 1990; 18: 282-285. [[Resumen](#)] [[Artículos relacionados](#)]
- 23.Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock? Chest 1993; 103: 1826-1831. [[Resumen](#)] [[Artículos relacionados](#)]
- 24.Martin C, Perrin G, Saux P, Papazian L, Gouin F. Effects of norepinephrine on right ventricular function in septic shock patients. Intensive Care Med 1994; 20: 444-447. [[Resumen](#)] [[Artículos relacionados](#)]
- 25.Martin C, Viviani X, Leone M, Thirion X. Effect of norepinephrine on the outcome of septic shock. Crit Care Med 2000; 28: 2758-2765. [[Resumen](#)] [[Artículos relacionados](#)]
- 26.Neviere R, Mathieu D, Chagnon JL, Lebleu N, Wattel F. The contrasting effects of dobutamine and dopamine on gastric mucosal perfusion in septic patients. Am J Respir Crit Care Med 1996; 154: 1684-1688. [[Resumen](#)] [[Artículos relacionados](#)]
- 27.O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002; 359: 1209-1210. [[Resumen](#)] [[Artículos relacionados](#)]
- 28.Palencia E. La resucitación precoz y guiada por objetivos hemodinámicos disminuye la mortalidad en la sepsis grave y el shock séptico. [[REMI 2001; 1 \(11\): 261](#)]
- 29.Power DA, Duggan J, Brady HR. Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: ineffective and probably dangerous. Clin Exp Pharmacol Physiol Suppl 1999; 26: S23-S28. [[Resumen](#)] [[Artículos relacionados](#)]
- 30.Rackow EC, Falk JL, Fein IA, Siegel JS, Packman MI, Haupt MT, Kaufman BS, Putnam D. Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit

- Care Med 1983; 11: 839-850. [[Resumen](#)] [[Artículos relacionados](#)]
- 31.Reinhart K, Kuhn HJ, Hartog C, Bredle DL. Continuous central venous and pulmonary artery oxygen saturation monitoring in the critically ill. Intensive Care Med 2004; 30: 1572-1578. [[Resumen](#)] [[Artículos relacionados](#)]
- 32.Rhodes A, Bennett ED. Early goal-directed therapy: An evidence-based review. Crit Care Med 2004; 32 (Suppl.): S448-S450. [[Resumen](#)] [[Artículos relacionados](#)]
- 33.Richer M, Robert S, Lebel M. Renal hemodynamics during norepinephrine and low-dose dopamine infusions in man. Crit Care Med 1996; 24: 1150-1156. [[Resumen](#)] [[Artículos relacionados](#)]
- 34.Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377. [[Resumen](#)] [[Artículos relacionados](#)]
- 35.Schreuder WO, Schneider AJ, Groeneveld AB, Thijs LG. Effect of dopamine vs norepinephrine on hemodynamics in septic shock. Emphasis on right ventricular performance. Chest 1989; 95: 1282-1288. [[Resumen](#)] [[Artículos relacionados](#)]
- 36.Sharma VK, Dellinger RP; SCCM. International Sepsis Forum. The International Sepsis Forum's controversies in sepsis: my initial vasopressor agent in septic shock is norepinephrine rather than dopamine. Crit Care 2003; 7: 3-5. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
- 37.Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 1988; 94: 1176-1186. [[Resumen](#)] [[Artículos relacionados](#)]
- 38.Shoemaker WC, Appel PL, Waxman K, Schwartz S, Chang P. Clinical trial of survivors' cardiorespiratory patterns as therapeutic goals in critically ill postoperative patients. Crit Care Med 1982; 10: 398-403. [[Resumen](#)] [[Artículos relacionados](#)]
- 39.Tuchschildt J, Fried J, Astiz M, Rackow E. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 1992; 102: 216-220. [[Resumen](#)] [[Artículos relacionados](#)]
- 40.Vincent JL, Gerlach H. Fluid resuscitation in severe sepsis and septic shock: An evidence based review. Crit Care Med 2004; 32 (Suppl.): S451-S453. [[Resumen](#)] [[Artículos relacionados](#)]
- 41.Yu M, Levy MM, Smith P, Takiguchi SA, Miyasaki A, Myers SA. Effect of maximizing oxygen delivery on morbidity and mortality rates in critically ill patients: a prospective, randomized, controlled study. Crit Care Med 1993; 21: 830-838. [[Resumen](#)] [[Artículos relacionados](#)]

## **Tratamiento antibiótico**

1. Bochud PY, Bonten M, Marchetti O, Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review. *Crit Care Med* 2004; 32 (Suppl.): S495–S512. [[Resumen](#)] [[Artículos relacionados](#)]
2. Garnacho-Montero J, García-Garmendia JL, Barrero-Almodóvar A, Jiménez-Jiménez FJ, Pérez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. *Crit Care Med*. 2003; 31: 2742-2751. [[Resumen](#)] [[Artículos relacionados](#)]
3. Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C, Cayuela A, Jimenez R, Barroso S, Ortiz-Leyba C. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. *Crit Care* 2006; 10: R111. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
4. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. *Am J Med* 2003; 115: 529-535. [[Resumen](#)] [[Artículos relacionados](#)]
5. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. *Chest* 2000; 118: 146-155. [[Resumen](#)] [[Artículos relacionados](#)] [[HTML](#)] [[PDF](#)]
6. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. *Chest* 1999; 115: 462-474. [[Resumen](#)] [[Artículos relacionados](#)] [[HTML](#)] [[PDF](#)]
7. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. *Clin Infect Dis* 2000; 31 Suppl 4: S131-S138. [[Resumen](#)] [[Artículos relacionados](#)] [[HTML](#)] [[PDF 90 Kb](#)]
8. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. *Crit Care Med* 2006; 34: 1589-1596. [[Resumen](#)] [[Artículos relacionados](#)]
9. MacArthur RD, Miller M, Albertson T, Panacek E, Johnson D, Teoh L, Barchuk W. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. *Clin Infect Dis* 2004; 38: 284-288. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo HTML](#)] [[PDF 114 Kb](#)]
10. Sandiumenge A, Díaz E, Bodí M, Rello J. Therapy of ventilator associated pneumonia. A patient-based approach based on the ten rules of "The Tarragona Strategy". *Intensive Care Med* 2003; 29: 876-883. [[Resumen](#)] [[Artículos relacionados](#)]
11. Shorr AF, Bodí M, Rodríguez A, Solé-Violán J, Garnacho-Montero J, Rello J for the CAPUCI Study Investigators. Impact of Antibiotic Guideline Compliance on Duration of Mechanical Ventilation in Critically Ill Patients with Community-Acquired Pneumonia. *Chest* 2006; 130: 93-100. [[Resumen](#)] [[Artículos relacionados](#)]
12. Vallés J, Rello J, Ochagavía A, Garnacho J, Alcalá MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy

**Sepsis grave y shock séptico: referencias bibliográficas. Versión 1, octubre 2006.**  
**Autor: Eduardo Palencia Herrejón. [REMI 2006; 6 \(10\): A55.](#)**

on survival. Chest 2003; 123: 1615-1624. [[Resumen](#)] [[Artículos relacionados](#)] [[HTML](#)]  
[[PDF](#)]

## ***Proteína C activada***

1. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL, for the Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death. *N Engl J Med* 2005; 353: 1332-1341. [[Resumen](#)] [[Artículos relacionados](#)]
2. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, López Rodríguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 2001; 344: 699-709. [[Resumen](#)] [[Artículos relacionados](#)]
3. De Backer D, Verdant C, Chierego M, Koch M, Gullo A, Vincent JL. Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. *Crit Care Med* 2006; 34: 1918-1924. [[Resumen](#)] [[Artículos relacionados](#)]
4. Dhainaut JF, Laterre PF, Janes JM, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple organ dysfunction: data from the PROWESS trial. *Intensive Care Med* 2003; 29: 894-903. [[Resumen](#)] [[Artículos relacionados](#)]
5. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. *Crit Care Med* 2003; 31: 12-19. [[Resumen](#)] [[Artículos relacionados](#)]
6. Fourrier F. Recombinant human activated protein C in the treatment of severe sepsis: An evidence-based review. *Crit Care Med* 2004; 32 (Suppl): S534-S541. [[Resumen](#)] [[Artículos relacionados](#)]
7. Green C, Dinnes J, Takeda A, Sheperd J, Hartwell D, Cave C, Payne E, Cuthbertson BH. Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation. *Health Technol Assess* 2005; 9: 1-126. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)] [[PDF 740 Kb](#)]
8. Laterre PF, Wittebole X. Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis- practical aspects at the bedside and patient identification. *Crit Care* 2003; 7: 445-450. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
9. Palencia E. Club de lectura: Proteína C activada en la sepsis grave: estudio PROWESS. [[REMI 2001; 1 \(3\) L1](#)]
10. Palencia E. Proteína C activada en la sepsis grave. [[REMI 2005; 5 \(6\): C28](#)]
11. Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. *Crit Care Med* 2003; 31: 834-840. [[Resumen](#)] [[Artículos relacionados](#)]
12. Vincent JI, Bernard GR, Beale R, Doig C et al. Drotecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment. *Crit Care Med* 2005; 33: 2266-2277. [[Resumen](#)] [[Artículos relacionados](#)]

**Sepsis grave y shock séptico: referencias bibliográficas. Versión 1, octubre 2006.**

**Autor: Eduardo Palencia Herrejón. [REMI 2006; 6 \(10\): A55.](#)**

13. Vincent JL, Nadel S, Kutsogiannis DJ, Gibney RTN, Yan SB, Wyss VL, Bailey JE, Mitchell CL, Sarwat S, Shinall SM, Janes JM. Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies. Crit Care 2005, 9:R331-R343. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
14. Vincent JL, O'Brien J Jr, Wheeler A, Wittebole X, Garg R, Trzaskoma BL, Sundin DP. Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis. Crit Care 2006; 10: R74. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]



### ***Determinación de lactato***

1. Friedman G, Berlot G, Kahn RJ, Vincent JL. Combined measurements of blood lactate concentrations and gastric intramucosal pH in patients with severe sepsis. Crit Care Med 1995; 23: 1184-1193. [[Resumen](#)] [[Artículos relacionados](#)]
2. Fukuoka T, Nishimura M, Imanaka H, Taenaka N, Yoshiya I, Takezawa J. Effects of norepinephrine on renal function in septic patients with normal and elevated serum lactate levels. Crit Care Med 1989; 17: 1104-1107. [[Resumen](#)] [[Artículos relacionados](#)]
3. Gallagher EJ, Rodriguez K, Touger M. Agreement between peripheral venous and arterial lactate levels. Ann Emerg Med 1997; 29: 479-483. [[Resumen](#)] [[Artículos relacionados](#)]
4. Gammaitoni C, Nasraway SA. Normal lactate/pyruvate ratio during overwhelming polymicrobial bacteremia and multiple organ failure. Anesthesiology 1994; 80: 213-216. [[Resumen](#)] [[Artículos relacionados](#)]
5. Meregalli A, Oliveira RP, Friedman G. Occult hypoperfusion is associated with increased mortality in hemodynamically stable, high-risk, surgical patients. Crit Care 2004; 8: R60-R65. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
6. Nguyen HB, Rivers EP, Knoblich BP, Jacobsen G, Muzzin A, Ressler JA, Tomlanovich MC. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004; 32: 1637-1642. [[Resumen](#)] [[Artículos relacionados](#)]
7. Michael W, Donnino MW, Nguyen B, Jacobsen G, Tomlanovich M, Rivers E. Cryptic Septic Shock: A Sub-analysis of Early, Goal-Directed Therapy. Chest Meeting Abstracts 2003 124: 90S-b. [[Resumen](#)] [[PDF](#)]
8. Shapiro NI, Howell MD, Talmor D, Nathanson LA, Lisbon A, Wolfe RE, Weiss JW. Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med 2005; 45: 524-528. [[Resumen](#)] [[Artículos relacionados](#)]

### ***Riesgo de muerte en sepsis grave y shock séptico***

1. Levy B, Dusang B, Annane D, Gibot S, Bollaert PE. Cardiovascular response to dopamine and early prediction of outcome in septic shock: A prospective multiple-center study. Crit Care Med 2005; 33: 2172-2177. [[Resumen](#)] [[Artículos relacionados](#)]
2. Peelen L, de Keizer NF, Peek N, Bosman RJ, Scheffer GJ, de Jonge E. Influence of entry criteria on mortality risk and number of eligible patients in recent studies on severe sepsis. Crit Care Med 2005; 33: 2178-2183. [[Resumen](#)] [[Artículos relacionados](#)]
3. Levy MM, Macias WL, Vincent JL, Russell JA, Silva E, Trzaskoma B, Williams MD. Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med 2005; 33: 2194-2201. [[Resumen](#)] [[Artículos relacionados](#)]

## **Corticoides en la sepsis y el SDRA**

1. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. *BMJ* 2004; 329: 480-488. [[Resumen](#)] [[Artículos relacionados](#)] [[PDF](#)] [[HTML](#)]
2. Annane D, Sébille V, Charpentier C, Bollaert PE, Francois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaut P, Bellissant E. Effects of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 2002; 288: 862-871. [[Resumen](#)] [[Artículos relacionados](#)]
3. Annane D, Sebille V, Troche G, Raphael JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. *JAMA* 2000; 283: 1038-1045. [[Resumen](#)] [[Artículos relacionados](#)]
4. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. *Crit Care Med* 1998; 26: 645-650. [[Resumen](#)] [[Artículos relacionados](#)]
5. Briegel J, Forst H, Haller M, Schelling G, Kilger E, Kuprat G, Hemmer B, Hummel T, Lenhart A, Heyduck M, Stoll C, Peter K. Stress doses of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study. *Crit Care Med* 1999; 27: 723-732. [[Resumen](#)] [[Artículos relacionados](#)]
6. Confalonieri M, Urbino R, Potena A et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. *Am J Respir Crit Care Med* 2005; 171: 242-248. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
7. Cristiane F. Pizarro, Eduardo J. Troster, Durval Damiani, Joseph A. Carcillo. Absolute and relative adrenal insufficiency in children with septic Shock. *Crit Care Med* 2005; 33: 855-859. [[Resumen](#)] [[Artículos relacionados](#)]
8. Keh D, Boehnke T, Weber-Carstens S et al. Immunologic and hemodynamic effects of "low-dose" hydrocortisone in septic shock: a double-blind, randomized, placebo-controlled, crossover study. *Am J Respir Crit Care Med* 2003; 167: 512-520. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
9. Keh D. Corticosteroid therapy in sepsis. Where are we?. *Adv Sepsis* 2006; 5: 138-140. [[Texto completo](#)]
10. Keh D, Sprung CL. Use of corticosteroid therapy in patients with sepsis and septic shock: An evidence-based review. *Crit Care Med* 2004; 32 [Suppl.]: S527-S533. [[Resumen](#)] [[Artículos relacionados](#)]
11. Minneci PC, Deans KJ, Banks SM, Eichacker PQ, Natanson C. Meta-Analysis: The effect of steroids on survival and shock during sepsis depends on the dose. *Ann Intern Med* 2004; 141: 47-56. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
12. Morel J, Venet C, Donati Y, Charier D, Liotier J, Frere-Meunier D, Guyomarc'h S, Diconne E. Adrenal axis function does not appear to be associated with hemodynamic improvement in septic shock patients systematically receiving glucocorticoid therapy. *Intensive Care Med* 2006; 32: 1184-1190. [[Resumen](#)] [[Artículos relacionados](#)]
13. Oppert M, Schindler R, Husung C, Offermann K, Graf KJ, Boenisch O, Barckow D, Frei U,

**Sepsis grave y shock séptico: referencias bibliográficas. Versión 1, octubre 2006.**  
**Autor: Eduardo Palencia Herrejón. [REMI 2006; 6 \(10\): A55.](#)**

- Eckardt KU. Low-dose hydrocortisone improves shock reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005; 33: 2457-2464. [[Resumen](#)] [[Artículos relacionados](#)]
14. Siraux V, De Backer D, Yalavatti G, Melot C, Gervy C, Mockel J, Vincent JL. Relative adrenal insufficiency in patients with septic shock: comparison of low-dose and conventional corticotropin tests. Crit Care Med 2005; 33: 2479-2486. [[Resumen](#)] [[Artículos relacionados](#)]
  15. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lankester PN, Hyzy R, Thompson BT, Ancukiewicz M; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354: 1671-1684. [[Resumen](#)] [[Artículos relacionados](#)]
  16. Weber-Carstens S, Deja M, Hokema F et al. Impact of continuous versus bolus low-dose hydrocortisone application on blood glucose in septic shock patients. Crit Care 2005; 9: P389. [[Resumen](#)]
  17. Yildiz O, Doganay M, Aygen B, Guven M, Kelestimur F, Tutus A. Physiological-dose steroid therapy in sepsis. Crit Care 2002; 6: 251-259. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]

## ***Catéter de arteria pulmonar***

1. Connors AF Jr, Speroff T, Dawson NV, Thomas C, Harrell FE Jr, Wagner D, Desbiens N, Goldman L, Wu AW, Califf RM, Fulkerson WJ Jr, Vidaillet H, Broste S, Bellamy P, Lynn J, Knaus WA. The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 1996; 276: 889-897. [[Resumen](#)] [[Artículos relacionados](#)]
2. Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, Brampton W, Williams D, Young D, Rowan K; PAC-Man study collaboration. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet 2005; 366: 472-477. [[Resumen](#)] [[Artículos relacionados](#)]
3. Harvey S, Stevens K, Harrison D, Young D, Brampton W, McCabe C, Singer M, Rowan K. An evaluation of the clinical and cost-effectiveness of pulmonary artery catheters in patient management in intensive care: a systematic review and a randomised controlled trial. Health Technol Assess 2006; 10 (29): 1-150. [[Resumen](#)] [[Artículos relacionados](#)] [PDF](#) versión resumida: 92 Kb, 6 pág] [[PDF](#) texto completo: 1,76 Mb, 166 pág]
4. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network; Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D, Wiedemann HP, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 2006; 354: 2213-2224. [[Resumen](#)] [[Artículos relacionados](#)]
5. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network; Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354: 2564-2575. [[Resumen](#)] [[Artículos relacionados](#)]
6. Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ, Laporta DP, Viner S, Passerini L, Devitt H, Kirby A, Jacka M; Canadian Critical Care Clinical Trials Group. A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med 2003; 348: 5-14. [[Resumen](#)] [[Artículos relacionados](#)]

### ***Lesión pulmonar aguda y SDRA***

1. Frutos-Vivar F, Nin N, Esteban A. Epidemiology of acute lung injury and acute respiratory distress syndrome. *Curr Opin Crit Care* 2004; 10: 1-6. [[Resumen](#)] [[Artículos relacionados](#)]
2. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. *N Engl J Med* 2005; 353: 1685-1693. [[Resumen](#)] [[Artículos relacionados](#)]
3. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. *N Engl J Med* 2000; 342: 1301-1308. [[Resumen](#)] [[Artículos relacionados](#)]
4. Ware LB, Matthay MA. The acute respiratory distress syndrome. *N Engl J Med* 2000; 342: 1334-1349. [[Resumen](#)] [[Artículos relacionados](#)]

## **Control de glucemias**

1. American Diabetes Association Position Statement, february 2006. Inpatient Diabetes and Glycemic Control: A Call for Action Conference. [[PDF](#) 71 Kb, 17 pág]
2. Bellomo R, Egi M. Glycemic control in the intensive care unit: why we should wait for NICE-SUGAR. Mayo Clin Proc 2005; 80: 1546-1548. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)] [[PDF](#)]
1. Brunkhorst FM, y col. Intensive insulin therapy in patient with severe sepsis and septic shock is associated with an increased rate of hypoglycemia. Infection 2005; 33 (Supl 1): 19. [Comunicación oral [PDF](#)] [Póster [PDF](#)]
2. Chant C, Wilson G, Friedrich JO. Validation of an insulin infusion nomogram for intensive glucose control in critically ill patients. Pharmacotherapy 2005; 25: 352-359. [[Resumen](#)] [[Artículos relacionados](#)]
3. Cryer PE, Davis SN, Shamon H. Hypoglycemia in diabetes. Diabetes Care 2003; 26: 1902-1912. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
4. Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. JAMA 2003; 290: 2041-2047. [[Resumen](#)] [[Artículos relacionados](#)]
5. Kanji S, Buffie J, Hutton B, Bunting PS, Singh A, McDonald K, Fergusson D, McIntyre LA, Hebert PC. Reliability of point-of-care testing for glucose measurement in critically ill adults. Crit Care Med 2005; 33: 2778-2785. [[Resumen](#)] [[Artículos relacionados](#)]
6. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003; 78: 1471-1478. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)] [[PDF](#)]
7. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc 2004; 79: 992-1000. [[Resumen](#)] [[Artículos relacionados](#)] [[PDF](#)]
8. Krinsley JS, Jones RL. Cost analysis of intensive glycemic control in critically ill adult patients. Chest 2006; 129: 644-650. [[Resumen](#)] [[Artículos relacionados](#)]
9. Malhotra A. Intensive insulin in intensive care. N Engl J Med 2006; 354: 516-518. [[Artículos relacionados](#)]
10. Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449-461. [[Resumen](#)] [[Artículos relacionados](#)]
11. Van den Berghe G, Wouters P, Weekers F, Verwaest Ch, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive Insulin Therapy in Critically Ill Patients. N Engl J Med 2001; 345: 1359-1367. [[Resumen](#)] [[Artículos relacionados](#)]
12. Van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P. Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 2003; 31: 359-366. [[Resumen](#)] [[Artículos relacionados](#)]
13. Vriesendorp TM, Devries JH, van Santen S, Moeniralam HS, de Jonge E, Roos YB, Schultz

MJ, Rosendaal FR, Hoekstra JB. Evaluation of short-term consequences of hypoglycemia in an intensive care unit. Crit Care Med 2006 Aug 29; [Epub ahead of print]. [[Resumen](#)] [[Artículos relacionados](#)]

14. Vriesendorp TM, van Santen S, DeVries JH, de Jonge E, Rosendaal FR, Schultz MJ, Hoekstra JB. Predisposing factors for hypoglycemia in the intensive care unit. Crit Care Med 2006; 34: 96-101. [[Resumen](#)] [[Artículos relacionados](#)]



## **Tratamiento de soporte**

1. Amarigiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis. *Cochrane Database Syst Rev* 2000; (3): CD001484. [[Resumen](#)] [[Artículos relacionados](#)]
2. Cariou A, Vinsonneau C, Dhainaut JF. Adjunctive therapies in sepsis: An evidence-based review. *Crit Care Med* 2004; 32 (Suppl.): S562-S570. [[Resumen](#)] [[Artículos relacionados](#)]
3. Cook D, Guyatt G, Marshall J, Leasa D, Fuller H, Hall R, Peters S, Rutledge F, Griffith L, McLellan A, Wood G, Kirby A. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. *N Engl J Med* 1998; 338: 791-797. [[Resumen](#)] [[Artículos relacionados](#)]
4. Cook DJ, Fuller HD, Guyatt GH, Marshall JC, Leasa D, Hall R, Winton TL, Rutledge F, Todd TJ, Roy P, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. *N Engl J Med* 1994; 10: 377-381. [[Resumen](#)] [[Artículos relacionados](#)]
5. Cook DJ, Reeve BK, Guyatt GH, Heyland DK, Griffith LE, Buckingham L, Tryba M. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. *JAMA* 1996; 275: 308-314. [[Resumen](#)] [[Artículos relacionados](#)]
6. Dive A, Foret F, Jamart J, Bulpa P, Installe E. Effect of dopamine on gastrointestinal motility during critical illness. *Intensive Care Med* 2000; 26: 901-907. [[Resumen](#)] [[Artículos relacionados](#)]
7. Esteban A, Alia I, Tobin MJ, Gil A, Gordo F, Vallverdu I, Blanch L, Bonet A, Vazquez A, de Pablo R, Torres A, de La Cal MA, Macias S. Effect of spontaneous breathing trial duration on outcome of attempts to discontinue mechanical ventilation. Spanish Lung Failure Collaborative Group. *Am J Respir Crit Care Med* 1999; 159: 512-518. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
8. Fennerty MB. Pathophysiology of the upper gastrointestinal tract in the critically ill patient: rationale for the therapeutic benefits of acid suppression. *Crit Care Med* 2002; 30: S351-S355. [[Resumen](#)] [[Artículos relacionados](#)]
9. Hebert PC, Wells G, Blajchman MA, Marshall J, Martin C, Pagliarello G, Tweeddale M, Schweitzer I, Yetisir E. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. *N Engl J Med* 1999; 340: 409-417. [[Resumen](#)] [[Artículos relacionados](#)]
10. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. *JAMA* 1995; 274: 335-337. [[Resumen](#)] [[Artículos relacionados](#)]
11. Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. *N Engl J Med* 2000; 342: 1471-1477. [[Resumen](#)] [[Artículos relacionados](#)]
12. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous

**Sepsis grave y shock séptico: referencias bibliográficas. Versión 1, octubre 2006.**  
**Autor: Eduardo Palencia Herrejón. REMI 2006; 6 (10): A55.**

- thromboembolism in acutely ill medical patients. *Circulation* 2004; 110: 874-879. [[Resumen](#)] [[Artículos relacionados](#)] [[Texto completo](#)]
13. Lorente JA, Landin L, De Pablo R, Renes E, Rodriguez-Diaz R, Liste D. Effects of blood transfusion on oxygen transport variables in severe sepsis. *Crit Care Med* 1993; 21: 1312-1318. [[Resumen](#)] [[Artículos relacionados](#)]
  14. Martin GS, Moss M, Wheeler AP, Mealer M, Morris JA, Bernard GR. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. *Crit Care Med* 2005; 33: 1681-1687. [[Resumen](#)] [[Artículos relacionados](#)]
  15. Sakr Y, Vincent JL, Reinhart K, Groeneveld J, Michalopoulos A, Sprung CL, Artigas A, Ranieri VM; Sepsis Occurrence in Acutely Ill Patients Investigators. High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. *Chest* 2005; 128: 3098-3108. [[Resumen](#)] [[Artículos relacionados](#)]
  16. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. *N Engl J Med* 1999; 341: 793-800. [[Resumen](#)] [[Artículos relacionados](#)]
  17. Trzeciak S, Dellinger RP. Other supportive therapies in sepsis: an evidence-based review. *Crit Care Med* 2004; 32: S571-S577. [[Resumen](#)] [[Artículos relacionados](#)]